Department of Neurological Sciences, Federico II University, Via Pansini 5, Naples, Italy
Hermitage Capodimonte IDC, Via Cupa delle Tozzole, Naples 80131, Italy
Biostructure and Bioimaging Institute (IBB), National Council for Research, Via Pansini 5, Naples, Italy
Neurology Unit, AORN Cardarelli, Naples 80131, Italy
References: Giovannoni, G., Munschauer III, F.E., Deisenhammer, F., Neutralising antibodies to interferon beta during the treatment of multiple sclerosis (2002) Journal of Neurology Neurosurgery and Psychiatry, 73 (5), pp. 465-469. , DOI 10.1136/jnnp.73.5.46
Neutralizing antibodies during treatment of multiple sclerosis with interferon Beta-1b: Experience during the first 3 years (1996) Neurology, 47, pp. 889-894. , The IFN-Beta Multiple Sclerosis Study Group The University of British Columbia MS/MRI Analysis Group
Rudick, R.A., Simonian, N.A., Alam, J.A., Campion, M., Scaramucci, J.O., Jones, W., Coats, M.E., Jacobs, L.D., Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis (1998) Neurology, 50 (5), pp. 1266-1272
Francis, G.S., Rice, G.P.A., Alsop, J.C., Interferon β-1a in MS: Results following development of neutralizing antibodies in PRISMS (2005) Neurology, 65 (1), pp. 48-55. , DOI 10.1212/01.wnl.0000171748.48188.5b
Rice, G.P.A., Paszner, B., Oger, J., Lesaux, J., Paty, D., Ebers, G., The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b (1999) Neurology, 52 (6), pp. 1277-1279
Sorensen, P.S., Ross, C., Clemmesen, K.M., Bendtzen, K., Frederiksen, J.L., Jensen, K., Kristensen, O., Koch-Henriksen, N., Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis (2003) Lancet, 362 (9391), pp. 1184-1191. , DOI 10.1016/S0140-6736(03)14541-2
Petkau, A.J., White, R.A., Ebers, G.C., Reder, A.T., Sibley, W.A., Lublin, F.D., Paty, D.W., Taylor, W., Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis (2004) Multiple Sclerosis, 10 (2), pp. 126-138. , DOI 10.1191/1352458504ms1004oa
Sbardella, E., Tomassini, V., Gasperini, C., Bellomi, F., Cefaro, L.A., Brescia Morra, V., Neutralizing antibodies explain the poor clinical response to interferon Beta in a small proportion of patients with multiple sclerosis: A retrospective study (2009) BMC Neurol, 9, p. 54. , 19825153 10.1186/1471-2377-9-54
Poser, C.M., Paty, D.W., Scheinberg, L., New diagnostic criteria for multiple sclerosis: Guidelines for research protocols (1983) Annals of Neurology, 13 (3), pp. 227-231. , DOI 10.1002/ana.410130302
Alfano, B., Brunetti, A., Larobina, M., Quarantelli, M., Tedeschi, E., Ciarmiello, A., Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis (2000) J Magn Reson Imaging, 12 (6), pp. 799-807. , 11105017 10.1002/15 22-2586(200 012)12:6<79 9::AID-JMR I2>
3.0.CO
2-# 1:STN:280:D C%2BD3M7htVaktA%3D%3D
Pungor Jr., E., Files, J.G., Gabe, J.D., Do, L.T., Foley, W.P., Gray, J.L., Nelson, J.W., Grossberg, S.E., A novel bioassay for the determination of neutralizing antibodies to IFN-β1b (1998) Journal of Interferon and Cytokine Research, 18 (12), pp. 1025-1030
Lanzillo, R., Prinster, A., Scarano, V., Liuzzi, R., Coppola, G., Florio, C., Salvatore, E., Brescia Morra, V., Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b (2006) Journal of the Neurological Sciences, 245 (1-2), pp. 141-145. , DOI 10.1016/j.jns.2005.08.023, PII S0022510X06001183
Spinnler, H., Tognoni, G., Standardizzazione e taratura italiana di test neuropsicologici (1987) Ital J Neurol Sci, 6 (S8), pp. 21-120
Amato, M.P., Ponziani, G., Siracusa, G., Sorbi, S., Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years (2001) Archives of Neurology, 58 (10), pp. 1602-1606
Goodin, D.S., Hurwitz, B., Noronha, A., Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis (2007) Journal of International Medical Research, 35 (2), pp. 173-187
Hoffmann, S., Cepok, S., Grummel, V., Lehmann-Horn, K., Hackermüller, J., Stadler, P.F., HLA-DRB1*0401 and HLA-RB1*0408 are strongly associated with the development of antibodies against interferon-Beta therapy in multiple sclerosis (2008) Am J Hum Genet, 83 (2), pp. 219-227. , 18656179 10.1016/j.ajhg.2008.07.006 1:CAS:528:DC%2BD1cXpvVOhs7s%3D
Confavreux, C., Vukusic, S., Adeleine, P., Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process (2003) Brain, 126 (4), pp. 770-782. , DOI 10.1093/brain/awg081
Okuda, D.T., Srinivasan, R., Oksenberg, J.R., Goodin, D.S., Baranzini, S.E., Beheshtian, A., Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures (2009) Brain, 132 (PART 1), pp. 250-259. , 19022862 1:STN:280:DC%2BD1M%2FptlWitw%3D%3D
Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Jacobs, L. D., Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis (1998) Neurology, 50 (5), pp. 1266-1272
Francis, G. S., Rice, G. P. A., Alsop, J. C., Interferon -1a in MS: Results following development of neutralizing antibodies in PRISMS (2005) Neurology, 65 (1), pp. 48-55. , DOI 10. 1212/01. wnl. 0000171748. 48188. 5b
Rice, G. P. A., Paszner, B., Oger, J., Lesaux, J., Paty, D., Ebers, G., The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon -1b (1999) Neurology, 52 (6), pp. 1277-1279
Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Koch-Henriksen, N., Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis (2003) Lancet, 362 (9391), pp. 1184-1191. , DOI 10. 1016/S0140-6736 (03) 14541-2
Petkau, A. J., White, R. A., Ebers, G. C., Reder, A. T., Sibley, W. A., Lublin, F. D., Paty, D. W., Taylor, W., Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis (2004) Multiple Sclerosis, 10 (2), pp. 126-138. , DOI 10. 1191/1352458504ms1004oa
Poser, C. M., Paty, D. W., Scheinberg, L., New diagnostic criteria for multiple sclerosis: Guidelines for research protocols (1983) Annals of Neurology, 13 (3), pp. 227-231. , DOI 10. 1002/ana. 410130302
2-# 1: STN: 280: D C%2BD3M7htVaktA%3D%3D
Amato, M. P., Ponziani, G., Siracusa, G., Sorbi, S., Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years (2001) Archives of Neurology, 58 (10), pp. 1602-1606
Goodin, D. S., Hurwitz, B., Noronha, A., Neutralizing antibodies to interferon -1b are not associated with disease worsening in multiple sclerosis (2007) Journal of International Medical Research, 35 (2), pp. 173-187
Okuda, D. T., Srinivasan, R., Oksenberg, J. R., Goodin, D. S., Baranzini, S. E., Beheshtian, A., Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures (2009) Brain, 132 (PART 1), pp. 250-259. , 19022862 1: STN: 280: DC%2BD1M%2FptlWitw%3D%3D
Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy
Vitiello M, Finamore E, Falanga A, Raieta K, Cantisani M, Galdiero F, Pedone C, Galdiero M, Galdiero S * Fusion in Coq(479 views) Lecture Notes In Computer Science (ISSN: 0302-9743, 0302-974335404636319783540463634, 0302-974335402975459783540297543), 2001; 2178LNCS: 583-596. Impact Factor:0.415 ViewExport to BibTeXExport to EndNote